论文部分内容阅读
目的探讨缬沙坦治疗高血压合并糖尿病患者血清脂联素的变化。方法将高血压合并糖尿病患者80例随机分为两组进行对比分析。结果与治疗前相比缬沙坦组显著降低了血清脂联素(P<0.01),氨氯地平组治疗前、后的脂联素改变异异无统计学意义。结论缬沙坦是一种新型的ARB,与其他ARBs比较,它具有药物浓度达峰快、半衰期长、生物利用度高等优点。因其分子结构与PPAR-γ激动剂吡格列酮相似,能部分激动PPAR-γ,是目前唯一可同时激动PPAR-γ又阻断AT1R的ARB,尤其适合高血压合并糖尿病患者的治疗。
Objective To investigate the changes of serum adiponectin in patients with hypertension complicated with diabetes treated with valsartan. Methods Eighty patients with hypertension and diabetes mellitus were randomly divided into two groups for comparative analysis. Results Compared with the pretreatment group, the serum adiponectin level was significantly lower in the valsartan group (P <0.01). There was no significant difference in the changes of adiponectin before and after treatment with amlodipine. Conclusion Valsartan is a new type of ARB. Compared with other ARBs, valsartan has the advantages of fast peak drug concentration, long half-life and high bioavailability. Because of its molecular structure similar to PPAR-γ agonist pioglitazone, it can partially activate PPAR-γ, and is the only ARB that can simultaneously activate PPAR-γ and block AT1R. It is especially suitable for the treatment of patients with hypertension and diabetes.